AI Engines For more Details: Perplexityβ Kagi Labsβ Youβ
Hyperkalemic Periodic Paralysis (HyperPP): Dichlorphenamide is indicated for the treatment of hyperkalemic periodic paralysis, a rare neuromuscular disorder characterized by episodes of muscle weakness or paralysis, typically triggered by high levels of potassium in the blood (hyperkalemia). Dichlorphenamide works by inhibiting the renal tubular reabsorption of sodium and potassium, leading to increased urinary excretion of potassium and normalization of serum potassium levels.
Hypokalemic Periodic Paralysis (HypoPP): Dichlorphenamide may also be used in the treatment of primary hypokalemic periodic paralysis, another rare neuromuscular disorder characterized by episodes of muscle weakness or paralysis associated with low levels of potassium in the blood (hypokalemia). The mechanism of action in hypokalemic periodic paralysis involves the enhancement of renal potassium reabsorption, leading to increased serum potassium levels and improvement of muscle function.
Symptom Management: Dichlorphenamide helps prevent or reduce the frequency and severity of paralytic episodes in individuals with hyperkalemic periodic paralysis or hypokalemic periodic paralysis. By stabilizing potassium levels in the blood and restoring normal neuromuscular function, dichlorphenamide can alleviate symptoms such as muscle weakness, cramping, stiffness, and paralysis during episodes of periodic paralysis.
Dosing and Administration: Dichlorphenamide is typically administered orally in tablet form, usually once or twice daily, as directed by a healthcare provider. The dosage may vary depending on the individual's age, weight, medical history, and response to treatment. It's important to follow the prescribed dosage and administration instructions carefully to achieve optimal therapeutic outcomes and minimize the risk of adverse effects.
Adverse Effects: Common side effects of dichlorphenamide may include tingling or numbness in the fingers or toes (paresthesias), fatigue, dizziness, headache, nausea, vomiting, diarrhea, and increased urination. More serious adverse effects such as metabolic acidosis, electrolyte disturbances, renal impairment, and hepatic dysfunction may occur rarely and require medical attention.
Contraindications: Dichlorphenamide is contraindicated in individuals with a known hypersensitivity or allergy to the medication or any of its components. It should be used with caution in individuals with pre-existing renal impairment, hepatic dysfunction, metabolic acidosis, electrolyte imbalances, or other medical conditions that may affect the safety or efficacy of dichlorphenamide therapy.
Monitoring: Regular monitoring of serum potassium levels, renal function, liver function, and electrolyte balance may be necessary during dichlorphenamide therapy to assess treatment response, detect adverse effects, and adjust dosage as needed. Healthcare providers may also recommend periodic evaluation of neuromuscular function and symptoms to ensure optimal management of periodic paralysis.
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive β X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. β Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA β Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. β Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. β Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]